Teneligliptin dosage of 20 to 40 mg helpful in patients with type II diabetes mellitus?

To study the efficacy of uptitrating the dose of Teneligliptin from 20 to 40 mg in patients with type II diabetes mellitus, researchers conducted a retrospective, comparative analysis in 853 type II diabetes mellitus patients who had follow-up records for more than 6 months.

The study was published in JAPI:

These patients were uncontrolled after use of atleast three oral antidiabetic drugs (OADs) and Teneligliptin 20 mg was added as the fourth drug. Patients who remained uncontrolled with the addition of 20 mg of Teneligliptin at the end of 3 months and were switched to receive 40 mg of Teneligliptin daily were included in this study. Results were analyzed at 3 and 6 months to ascertain efficacy of high-dose (40 mg) Teneligliptin. All other oral antidiabetic drugs remained the same in both groups. In all patients, the fasting blood glucose, postprandial blood glucose, and hemoglobin A1c (HbA1C) were evaluated and compared.

At the end of 3 months after using Teneligliptin 40 mg, the mean reduction in HbA1C was 0.5%. Similarly, mean reduction in fasting blood sugar (FBS) and postprandial blood sugar (PPBS) was 6.5 and 3.6 mg/dL, respectively. At the end of 6 months after using Teneligliptin 40 mg HbA1C showed no change but mean FBS and PPBS showed a modest reduction.

The authors hence, concluded that the results showed no statistically significant improvement in glycemic parameters when dose of Teneligliptin was increased from 20 to 40 mg at 3 months. But at 6 months, the FBS and PPBS showed a modest reduction but the HbA1C showed no change.

Reference:

Panikar V, Joshi S, Tiwaskar M, et al. Study of the Efficacy of Uptitrating Teneligliptin Dose from Standard Dose (20 mg) to High Dose (40 mg) in Patients with Type II Diabetes Mellitus. J Assoc Physicians India 2022;70(7):76–78.